Crude plasma membrane fractions were prepared from female Wistar rat anterior pituitaries. These fractions contained a single population of specific 3H-labeled [8- Corticotropin-releasing factor activated, and angiotensin inhibited, the adenylate cyclase activity of pituitary membranes. Under the same experimental conditions, vasopressin did not influence adenylate cyclase activity nor did it affect the corticotropin-releasing factor-induced activation. These data support the view that vasopressin is one component of the multifactorial regulation of corticotropin release and that it acts through a cAMP-independent pathway. The potentiation by vasopressin of corticotropin-releasing factor-induced cAMP accumulation in intact cells very likely proceeds through indirect mechanisms, which are not expressed in broken cell preparations.
Corticotropin-releasing factor activated, and angiotensin inhibited, the adenylate cyclase activity of pituitary membranes. Under the same experimental conditions, vasopressin did not influence adenylate cyclase activity nor did it affect the corticotropin-releasing factor-induced activation. These data support the view that vasopressin is one component of the multifactorial regulation of corticotropin release and that it acts through a cAMP-independent pathway. The potentiation by vasopressin of corticotropin-releasing factor-induced cAMP accumulation in intact cells very likely proceeds through indirect mechanisms, which are not expressed in broken cell preparations.
Despite abundant evidence (1-6) that the 41-residue peptide recently isolated from ovine hypothalami (7) is a physiological corticotropin-releasing factor (CRF), the hypothalamic factor responsible for the integrated release of corticotropin (ACTH) seems not to be a single peptide but a multifactorial complex (8, 9) . Vasopressin has been proposed as a constituent of this complex (9, 10) . There are several pieces of evidence in favor of this concept: the synergism observed between ovine CRF and vasopressin (10, 11) ; the coexistence of immunoreactive neurophysin/vasopressin and CRF in nerve terminals of the zona externa of the median eminence (12) and in cells of the paraventricular nucleus (13); and finally high levels of vasopressin in portal blood (14) . Further support for the role of vasopressin in the CRF complex includes the potentiation of the Brattleboro rat CRF activity by addition of synthetic vasopressin (15) and recent chromatographic investigations (9, 15) .
Nevertheless, the properties of vasopressin receptors that confer CRF activity are not well defined. The relationship between CRF and pressor or antidiuretic attivity of various vasopressin analogues is in dispute (16) (17) (18) (19) (20) . Recently Aizawa et al. found that CRF and pressor activities of several vasopressin analogues were strongly correlated, whereas CRF and antidiuretic activities were hot (21) . These data were obtained from in vivo experiments; therefore, it cannot be ascertained that the CRF effects of the analtgues were due to a direct effect on the pituitary. This CRF effect may indeed be due to the vasoconstrictor action of these drugs, which could indirectly induce corticotropin secretion through some intermediary mechanism.
Although a role for vasopressin as a physiological CRF is now being considered, the characterization of pituitary vasopressin receptors is still missing. This 8 Ci/mM; 1 Ci = 37 GBq) was prepared as described (22) . [3H]Vasopressin was purified by affinity chromatography using neurophysin-Sepharose columns. The biological activities of the labeled peptide were found indistinguishable from those of the starting materials (synthetic [8-lysine] vasopressin from UCB Bau Products SA, Brussels, Belgium). The following peptides were used: [8-arginine]vasopressin ([Arg8]VP), [8-lysinelvasopressin (20 pum) and then centrifuged at 30,000 x g for 30 min. The pellet was resuspended in cold binding assay buffer and used immediately. For the adenylate cyclase assay, six adenohypophyses were homogenized in 1 ml of TES buffer (1 mM Tris maleate, pH 7.2/1 mM EGTA/10% sucrose). The homogenate was filtered through a silk screen (0.2-mm pore size) and diluted with 2 ml of TES buffer without sucrose. The membrane suspension was centrifuged at 10,000 x g for 15 min, and the pellet resuspended in 1.5 ml of TES buffer. A total of 11 membrane preparations was used.
The isolated rat anterior pituitary cell column used for CRF bioassays was prepared as described by Gillies and Lowry (23) . Briefly, the cells from five adenohypophyses were dispersed by mechanical agitation in 0.25% trypsin solution, mixed with 0.5 g of preswollen Bio-Gel P-2 (200-400 mesh), and packed into a 2-ml plastic column (0.9 x 3 cm).
The column was washed with EBSS containing 0.05% lima bean trypsin inhibitor and subsequently was perfused at a rate of 0.5 ml/min with EBSS containing ascorbic acid (50 pug/ml), 0.25% human serum albumin, Trasylol (100 kallikrein inactivation units/ml) and antibiotics (15 Ag of benzyl penicillin and 25 pg of streptomycin per ml).
Crude stalk median eminence extracts were prepared as follows. The hypothalamic-hypophysial stalk, with a small area of median eminence approximately 3 mm in diameter surrounding it (3-4 mg wet weight) was removed at the same time as the pituitaries. The median eminence fragments were homogenized in 0.01 M HCl containing ascorbic acid (1 mg/ml) at a concentration of 1 median eminence extract per ml. After neutralization with 1.1 M NaHCO3 (10 ,.d/ml) and addition of NaCl (9 mg/ml) and Trasylol (250 units/ml), the extract was centrifuged (20 min at 3,000 x g), and the supernatant was frozen until used in binding assays.
[ There was a fairly good correspondence between the Kd deduced from the association (k1) and dissociation (kL1) rate constants (k1 = 2.1 x 1 M'1min-'; kL1 = 0.17 min-'; Kd = 8.1 x 10-M) and that derived from dose-dependent binding at equilibrium (Kd = 5.6 x 10-9 M). A mean Kd value of 8 ± 2 (SD) x 10-9 M, deduced from seven independent determinations, was close to those determined for vasopressin receptors in rat liver membranes (26) and rat aortic myocytes (27) . It was higher than that of adenylate cyclase-coupled vasopressin receptors from rat kidney membranes (28 Fig. 2 . The results obtained are summarized in Table 1 together with the results of the determination of the CRF-like activities of these analogues. When comparing these two sets of data, a good correlation between the relative affinities of the tested analogues for pituitary membranes and the corresponding relative potencies in inducing corticotropin release could be demonstrated (see Table 1 nM have been determined in the hypophysial portal blood in the monkey (14) .
Data shown in Table 1 also indicate that the order of potency found for the binding of the tested analogues to the hypophysial membranes is similar to that found in the rat vasopressor assay. It is markedly different from that found in the rat antidiuretic assay. Thus, analogues exhibiting a high vasopressor/antidiuretic activity ratio such as [ (26) , inhibited by GTP and ATP in a dose-dependent manner. However, this effect which occurred in 0.1 mM range, is markedly different from the well-documented GTP effect on adenylate cyclase-coupled receptors (37) . Fig. 5 (6, 7, 10, 39, 40) . The multimolecular nature of the hypothalamic factor responsible for corticotropin release is an attractive hypothesis because of the variety of stress situations. A CRF complex would provide a highly sensitive mechanism regulating very finely the stress hormone in response to a whole variety of endogenous and exogenous stimuli. Therefore, the various factors would have specific roles in various stress situations, and vasopressin may not play a role in all of them (41) . This may explain some of the controversies about the physiological involvement of vasopressin in corticotropin release. 
